Swiss ministers have met with senior executives of pharmaceutical companies Roche and Novartis to discuss the outlook for the ...

Switzerland’s economic growth slowed sharply in the second quarter as U.S. tariff frontrunning seen earlier in the year ...

Roche (RHHBY) and Novartis (NVS) are scheduled to meet with Swiss officials this week amid U.S. tariff threats on pharma ...

The Swiss government is due to meet this week with pharmaceuticals firms that U.S. President Donald Trump has asked to lower ...

Switzerland’s government has reached out to local drugmakers Roche Holding AG and Novartis AG to discuss the tariff situation ...

The Swiss government met with executives of Roche Holding AG and Novartis AG to discuss the pharmaceutical industry’s situation in light of US tariffs.

The Swiss government has met with senior executives from Roche (ROG: SIX) and Novartis (NOVN: VX) to discuss the outlook for ...

Swiss ministers met with senior executives from Roche and Novartis to discuss the potential impact of U.S. import tariffs on pharmaceuticals. While pharmaceuticals currently avoid these tariffs, an ...

The Swiss government is engaging with pharma companies Roche and Novartis to address U.S. President Trump's demand for price cuts and to negotiate a 39% tariff on Swiss exports. The discussion follows ...

President Donald Trump’s announcement about tariffs on pharmaceutical goods imported to the United States is delayed. | ...

Switzerland’s economy unexpectedly grew in the second quarter, maintaining some momentum before the country was hit with one of the highest US tariff rates.

Good news in research for Novartis. The pharmaceutical giant has achieved the hoped-for results for Ianalumab, a candidate for the treatment of Sjögren’s Syndrome, a serious autoimmune disease.